ArticleACR open rheumatology2026
Endothelial Dysfunction in Systemic Sclerosis: The Passive Leg Movement Technique in the Assessment of Nitric Oxide-Mediated Vascular Impairment.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the impairment of nitric oxide (NO)-mediated vascular function in patients with systemic sclerosis (SSc) compared with healthy controls through passive leg movement (PLM), which is a noninvasive technique largely dependent on NO bioavailability.
methodsTwenty-one patients with SSc and 21 age- and sex-matched healthy controls were recruited. PLM was performed in a sitting position, and blood flow was assessed at the level of the right common femoral artery, distal to the inguinal ligament, and approximately 2 cm from the femoral artery bifurcation, by measuring flow velocity and vessel diameter. Resting blood flow, peak flow during PLM, and the area under the blood flow versus time curve (AUC) were calculated. Patients with SSc were stratified by disease phenotype and treatment regimens.
resultsPatients with SSc showed significantly reduced PLM responses compared with controls (peak flow: 467.7 ± 97.8 vs 552.5 ± 151.9, P = 0.038; ΔPeak:153.3 ± 59.8 vs 220.2 ± 82.7, P = 0.005; AUC: 57.1 ± 38.9 vs 89.3 ± 38.1, P = 0.01), indicating impaired NO-mediated vasodilation. No significant differences in PLM results were found across SSc phenotypes. An inverse correlation was observed between modified Rodnan Skin Score and femoral artery diameter (P = 0.001), suggesting vascular remodeling. Pharmacologic treatments, including vasoactive and immunosuppressive agents, did not significantly impact PLM parameters. Statin use was associated with lower baseline blood flow (P = 0.031).
conclusionPLM responses are significantly reduced in patients with SSc, confirming the role of NO-mediated endothelial dysfunction in SSc, independent of disease subtype or treatment status. PLM may serve as a noninvasive biomarker for microvascular health in SSc and underscore the need for therapies that directly target the endothelium. Larger, longitudinal studies are warranted to confirm these results and explore PLM's prognostic utility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.